EQL Pharma AB (publ) (STO:EQL)

Revenue by Segment

Financials in millions SEK. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Dec 31, 2017
Generics for Prescription Pharmacy Sales and Hospital Sales	432.66M	373.52M	264.17M	259.91M	409.75M
Total	432.66M	373.52M	264.17M	259.91M	409.75M

Revenue by Geography

Financials in millions SEK. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Dec 31, 2017
Sweden	144.66M	164.83M	145.28M	162.77M	365.22M
Other Europe	91.16M	55.74M	28.24M	9.72M	-
Outside Europe	835.00K	553.00K	-	-	-
Denmark	162.14M	106.48M	57.21M	68.90M	-
Norway	21.03M	32.16M	26.55M	15.83M	-
Finland	12.84M	13.75M	6.89M	2.69M	-
Scandinavia	-	-	-	-	44.54M
Total	432.66M	373.52M	264.17M	259.91M	409.75M

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 23, 2026

Data Sources Report a data error